Refile: BRIEF-Fresenius And Wuxi Biologics Enter Exclusive Development Agreement To Expand Biosimilars Pipeline

Fresenius SE & Co. KGaA

Mon 06:08

Refiles to add relevant Reuters Instrument Code.
Nov 2 (Reuters) - 
FRESENIUS AND WUXI BIOLOGICS ENTER EXCLUSIVE DEVELOPMENT AGREEMENT TO EXPAND BIOSIMILARS PIPELINE
FRESENIUS WILL DETERMINE LONG-TERM MANUFACTURING STRATEGY FOR EACH CANDIDATE, WITH OPTIONALITY TO LEVERAGE MABXIENCE NETWORK, WHOLLY OWNED SINCE OCTOBER 2026
AGREEMENT GIVES FRESENIUS FULL STRATEGIC FLEXIBILITY TO SELECT AND ADVANCE BIOSIMILAR CANDIDATES TO DEVELOP, AGAINST ITS ESTABLISHED SELECTION CRITERIA, WHILE RETAINING FULL COMMERCIALIZATION ECONOMICS OF PRODUCTS UNDER AGREEMENT
EXCLUSIVE OPTION RIGHTS FOR UP TO 37 POTENTIAL FIRST-TO-MARKET BIOSIMILAR CANDIDATES TO SIGNIFICANTLY EXPAND FRESENIUS' PORTFOLIO
NEXT-GENERATION PORTFOLIO SPANS 13 THERAPEUTIC AREAS AND MULTIPLE BIOLOGIC TECHNOLOGIES, INCLUDING MONOCLONAL AND BISPECIFIC ANTIBODIES, ANTIBODY-DRUG CONJUGATES AND FUSION PROTEINS
PROVIDES ACCESS TO INCREASE PORTFOLIO FROM 29 MARKETED AND PIPELINE MOLECULES TODAY TO UP TO 66 MOLECULES
IT PROVIDES ACCESS TO A SCALABLE PATHWAY TO INCREASE PORTFOLIO , ADDRESSING MORE THAN EUR 370 BILLION IN ORIGINATOR LIST-PRICE-BASED-SALES
Further company coverage: [FREn.DE]

 (Gdansk Newsroom)
 ((Reuters Messaging: Gdansk.newsroom@thomsonreuters.com ; +48 58 7696600))